RNATICS develops novel, first-in-class RNA therapeutics to target disease-causing, regulatory RNAs in macrophages. This innovative way of delivery through immune cells enables access to organs previously not accessible to RNA therapy offering tremendous therapeutic opportunities for multiple diseases.The most advanced drug candidate, RCS-21, is currently in development for the treatment by inhalation of patients with severe cases of viral respiratory infections, such as COVID-19.